Cortexin

Cortexin is a Russian-developed pharmaceutical preparation derived from porcine cerebral cortex. It is a complex polypeptide mixture rather than a single defined peptide, consisting of low-molecular-weight peptides (below 10 kDa) and amino acids. Manufactured by Geropharm in St. Petersburg, the product is registered as a prescription pharmaceutical in Russia and several CIS countries. Standard formulation: 10 mg lyophilized powder per vial, reconstituted with 0.5% procaine solution or 0.9% sodium chloride for intramuscular injection. Standard course: 10 mg daily for 10 consecutive days, repeated 1-2 times per year. Indications in Russian clinical practice include post-stroke recovery, traumatic brain injury rehabilitation, pediatric encephalopathy and developmental disorders, perinatal encephalopathy in infants, cognitive impairment associated with cerebrovascular disease, and ADHD. The proposed mechanism involves neurotrophic and neuroprotective effects through the complex peptide mixture, with effects on neurotransmitter balance, neuronal apoptosis, and BDNF expression. Some randomized Russian trials exist (Skoromets 2017 for ischemic stroke) but Western peer-reviewed clinical trial evidence is essentially absent. Cortexin is not approved by FDA or EMA.

Composition and Manufacturing

Cortexin is manufactured by Geropharm (formerly Pharma VAM/Pharmamed) in St. Petersburg, Russia. The manufacturing process involves:

• Extraction from porcine cerebral cortex tissue
• Acid hydrolysis to break down larger proteins
• Filtration and purification steps
• Selection of the low-molecular-weight fraction (below 10 kDa)
• Lyophilization for stability

The final product is a complex mixture containing:

• Low-molecular-weight neuropeptides (variable composition)
• Free amino acids
• Some bioactive peptide fragments
• Trace components

The exact peptide composition has been characterized to varying degrees in the Russian scientific literature but is not described at the level of a single defined molecular entity. The product specification controls for total polypeptide content, specific manufacturing parameters, and biological activity assays rather than precise identification of every component.

This is distinct from:

• Khavinson bioregulators (Pinealon, Epitalon, Vesugen): synthetic single peptides with defined sequences
• Single peptide nootropics (Semax, Selank): synthetic peptides with defined structures
• Cerebrolysin: a similar porcine brain-derived peptide preparation (more comparable to Cortexin)

The Cerebrolysin Comparison

Cortexin is most similar to Cerebrolysin in composition and clinical use:

• Both are porcine brain-derived peptide preparations
• Both contain low-molecular-weight peptides and amino acids
• Both are used clinically in Russia and parts of Europe for stroke, TBI, and dementia
• Both have similar proposed neurotrophic mechanisms
• Cerebrolysin has a slightly stronger international evidence base (some Cochrane reviews exist), though still limited by Western standards

Differences:

• Cerebrolysin: from porcine whole brain (cerebral hemispheres). Different manufacturer (Ever Pharma, Austria). Different specific preparation. Some Western European clinical use
• Cortexin: from porcine cerebral cortex specifically. Geropharm manufacturer. Primarily Russian/CIS clinical use. Less Western European presence

The mechanistic logic and clinical positioning are very similar between the two products.

Skoromets 2017 Ischemic Stroke Trial

One of the more rigorous Cortexin clinical trials is the Skoromets and colleagues 2017 International Journal of Stroke publication:

• Design: randomized, double-blind, placebo-controlled
• Population: 272 patients with acute ischemic stroke
• Intervention: Cortexin 10 mg intramuscularly daily for 10 days vs placebo
• Endpoint: modified Rankin Scale and other functional outcomes at 30 days
• Results: Cortexin group showed statistically significant improvement in functional outcomes compared to placebo
• Strengths: randomization, blinding, placebo control, peer-reviewed Western journal publication
• Limitations: single trial, Russian patient population, mechanism not fully elucidated

This trial provides the strongest available evidence for Cortexin efficacy in a specific neurological indication by Western methodological standards. It supports Cortexin's use in acute ischemic stroke within the Russian clinical context but has not been replicated by independent Western groups, and the FDA would require additional pivotal trial data for approval.

Clinical Indications in Russian Practice

Cortexin is used clinically in Russia and CIS countries for:

Pediatric neurology:

• Perinatal encephalopathy in infants
• Cerebral palsy supportive treatment
• Developmental delays
• ADHD
• Various pediatric epileptic syndromes (as adjunct, not replacement for antiepileptics)
• Childhood cognitive disorders

Adult neurology:

• Acute ischemic stroke (within first 1-2 weeks)
• Subacute and chronic post-stroke rehabilitation
• Traumatic brain injury (acute and rehabilitation phases)
• Vascular dementia and mild cognitive impairment
• Chronic cerebrovascular insufficiency
• Post-COVID cognitive symptoms (in some recent Russian guidelines)

Less common Russian uses:

• Asthenic syndromes
• Various chronic fatigue presentations
• Adjunct in epilepsy management
• Migraine prophylaxis (limited evidence)

The breadth of indications reflects Russian clinical practice patterns. Western regulatory authorities would require specific clinical trial evidence for each indication before approval.

Russian Clinical Studies

Russian-language clinical literature on Cortexin includes:

• Numerous case series and observational studies in pediatric populations
• Several randomized trials in stroke recovery (Skoromets 2017 being the most rigorous English-language publication)
• Studies in chronic cerebrovascular insufficiency
• Observational data on TBI rehabilitation
• Pediatric cognitive enhancement studies
• Combination studies with other Russian neuropharmacology (Cerebrolysin, Semax, Selank)

The Russian evidence base is substantial in volume but variable in methodological quality. Many studies use less rigorous designs (open-label, historical controls) than Western standards would require.

Absence of Western Clinical Trials

Outside the Skoromets 2017 publication, Western peer-reviewed clinical trial evidence for Cortexin is largely absent:

• No major Phase 3 trials registered with FDA or EMA
• Limited inclusion in Cochrane systematic reviews
• Minimal coverage in mainstream Western neurology journals
• Not included in standard Western neurology guidelines for stroke, TBI, or dementia

This is partially due to:

• Geropharm's primary focus on Russian and CIS markets
• Western regulatory pathway costs and complexity
• The compositional complexity of the preparation challenges Western single-molecule pharmaceutical paradigms

Regulatory Status

• FDA: Not approved
• EMA: Not approved
• Russia: Approved pharmaceutical drug, Geropharm registration
• Ukraine, Belarus, Kazakhstan, other CIS: Approved
• WADA: Not on the prohibited list. Some athletes in Russian sports federations have used Cortexin without WADA violations (though this could change if specific concerns emerged)

Cortexin's mechanism is challenging to define precisely because the product is a complex mixture rather than a single defined molecule. The proposed mechanisms are based on Russian preclinical research, animal studies, and inferences from neuropharmacology of similar brain-derived peptide preparations.

Neurotrophic Effects

The principal proposed mechanism is neurotrophic support:

• BDNF (brain-derived neurotrophic factor) effects: animal studies suggest Cortexin increases BDNF expression in brain tissue
• NGF (nerve growth factor) effects: related neurotrophic effects through nerve growth factor signaling
• Neuronal survival: reduced apoptosis in stress models
• Axonal and dendritic plasticity: support for synaptic remodeling
• Neurogenesis: possible support for adult neurogenesis in hippocampus (limited evidence)

Neurotransmitter Balance

Cortexin is proposed to regulate neurotransmitter balance:

• GABA-glutamate balance: reduced excitotoxicity through GABAergic support and reduced glutamate excess
• Acetylcholine system: support for cholinergic neurotransmission
• Dopaminergic effects: some evidence for dopaminergic modulation
• Serotonergic effects: limited evidence for serotonin system modulation

Antioxidant and Anti-Inflammatory Effects

The Plotnikov 2015 Bulletin of Experimental Biology and Medicine paper reports antioxidant effects in cerebral ischemia:

• Reduced oxidative stress markers
• Reduced inflammatory cytokines
• Reduced apoptotic markers
• Improved mitochondrial function in stressed neurons

Effects on Cerebral Hemodynamics

Some evidence suggests effects on cerebral blood flow regulation, particularly in pediatric and post-stroke contexts. The specific mechanisms are not fully characterized.

Pharmacokinetics

The pharmacokinetics of Cortexin are difficult to characterize precisely because of the complex composition:

• Intramuscular injection produces systemic absorption of the peptide and amino acid components
• Blood-brain barrier penetration of larger peptide components is questionable
• Free amino acid components are readily distributed
• Smaller peptide fragments can potentially cross the blood-brain barrier
• Detailed PK data per individual peptide component is not available
• The mechanism of action may include both direct CNS effects of penetrating components and indirect systemic effects with downstream CNS consequences

Mechanism in Comparison to Single-Peptide Nootropics

The complex tissue-extract nature of Cortexin makes its mechanism fundamentally different from single-peptide nootropics like Semax or Selank:

• Semax/Selank: defined synthetic peptides with specific receptor or neurotransmitter targets
• Khavinson bioregulators: defined synthetic peptides with proposed tissue-specific gene regulation
• Cortexin/Cerebrolysin: complex tissue extracts with multiple components and multiple proposed mechanisms

This complexity is both a potential strength (multiple complementary effects) and a methodological challenge (difficult to characterize and standardize).

Effects in clinical use (Russian clinical practice, including the Skoromets 2017 trial and broader Russian literature):

• Improved functional recovery after ischemic stroke
• Improved cognitive function after TBI
• Improved developmental outcomes in pediatric encephalopathy
• Reduced symptoms of perinatal encephalopathy in infants
• Improved cognitive function in vascular dementia patients
• Improved attention and behavior in ADHD pediatric populations
• Reduced asthenic symptoms in chronic cerebrovascular insufficiency

Effects in animal models:

• Neuroprotection in cerebral ischemia models
• Reduced infarct volume in MCA occlusion models
• Improved cognitive performance in lesioned animals
• Reduced markers of oxidative stress and apoptosis
• Increased BDNF expression

Effects in pediatric clinical experience:

• Improvements in cognitive function and behavioral measures
• Reduced symptoms of perinatal brain injury
• Effects on motor development (limited controlled evidence)
• Generally well-tolerated in pediatric populations

Effects in Western peer-reviewed clinical trials: limited. The Skoromets 2017 ischemic stroke trial is one of few examples. No Phase 3 development program by Western pharmaceutical standards.

Honest evidence framing: Cortexin has substantial Russian clinical use across multiple neurological indications, with some randomized controlled trial evidence (most notably Skoromets 2017 for acute ischemic stroke). The mechanism of action through neurotrophic, antioxidant, and neurotransmitter effects is biologically plausible based on the porcine brain-derived peptide mixture composition. However, the complex composition challenges the single-molecule pharmacology paradigm of Western regulatory frameworks. Western peer-reviewed clinical trial evidence is limited beyond the Skoromets 2017 trial. The breadth of Russian clinical indications exceeds what would be supported by Western evidence standards. For Western patients considering Cortexin, the practical considerations include the unproven status by Western evidence standards, sourcing and quality verification challenges, and the legal context (not approved in Western jurisdictions).

Standard Russian adult dosing:

• 10 mg intramuscularly once daily for 10 consecutive days
• Course repeated 1-2 times per year as clinically indicated
• Some severe cases: 20 mg daily (10 mg morning + 10 mg evening) for 10 days

Pediatric dosing:

• Children under 20 kg: 0.5 mg/kg intramuscularly daily for 10 days (typically 5 mg)
• Children 20 kg and above: 10 mg daily for 10 days
• Infants: weight-based, typically 0.5 mg/kg

Reconstitution:

• The 10 mg lyophilized powder vial is reconstituted with 1-2 mL of:
  • 0.5% procaine solution (Russian standard, provides local anesthesia for injection comfort)
  • 0.9% sodium chloride (alternative if procaine-allergic)
  • Water for injection (less common)
• Mix gently, avoid vigorous shaking
• Use immediately after reconstitution
• Do not store reconstituted solution

Injection technique:

• Intramuscular injection into gluteal or thigh muscle
• Standard 23-25G needle, 1-1.5 inch length
• Aspirate before injection
• Slow injection (1-2 minutes per 1 mL)
• Rotate injection sites between courses

Treatment course structure:

• 10-day intensive course is standard
• Inter-course interval typically 1-3 months minimum
• For pediatric perinatal encephalopathy: often 2-3 courses per year for the first 2-3 years
• For stroke recovery: 1-2 courses during initial 6 months post-stroke
• For TBI: 1-3 courses depending on severity and recovery phase
• For chronic indications (vascular dementia, ADHD): cyclical maintenance over years

Special populations:

• Pregnancy: contraindicated. Not adequately studied
• Breastfeeding: avoid
• Pediatric: extensively used in Russian pediatric neurology with weight-based dosing
• Severe renal impairment: caution, no specific Russian dosing guidelines
• Severe hepatic impairment: caution
• Active autoimmune disease: theoretical caution given protein-derived nature
• Allergy to porcine proteins: contraindicated
• History of severe allergic reactions: caution

Sourcing considerations:

• Geropharm is the original and primary manufacturer
• Counterfeit products exist in international markets
• Identity verification and quality assurance depend on legitimate Russian/CIS pharmacy sourcing
• Cold chain not required for the lyophilized product but recommended for stored stock

Adverse effects observed in Russian clinical practice and the Skoromets 2017 trial:

• Generally well-tolerated
• Injection site reactions (pain, mild redness, occasional induration): common
• Local procaine reaction at injection site: relates to the reconstitution diluent
• Mild allergic reactions (rash, itching): uncommon
• Severe allergic reactions including anaphylaxis: rare but reported (porcine protein origin)
• Mild headache: occasional
• Mild dizziness: occasional
• Mild excitement or sleep disturbance: occasional, particularly with evening dosing
• Mild gastrointestinal effects: uncommon

Theoretical concerns:

• Allergic reactions to porcine proteins: significant practical concern. Patients with known pork allergies or porcine protein hypersensitivity should not receive Cortexin
• Transmissible pathogen risk: theoretical concern for any animal-tissue-derived product. Russian regulatory standards include pathogen screening, but Western standards may differ. The risk of prion disease, viral contamination, or other transmissible agents is theoretical but not zero
• Autoimmune induction: theoretical concern for peptide preparations derived from foreign animal tissue
• Long-term safety in Western populations: not characterized in rigorous prospective studies
• Drug interactions: not systematically studied with Western medications
• Effects in active malignancy: theoretical caution
• Quality variability: between manufacturers and lots

Contraindications:

• Known hypersensitivity to porcine proteins
• Pregnancy
• Breastfeeding
• Severe acute allergic reactions to prior peptide preparations

Cautions:

• History of severe allergies
• Active autoimmune disease
• Active malignancy (relative caution)
• Severe renal or hepatic impairment

Drug interactions:

• Not systematically studied
• Procaine reconstitution: interactions with sulfonamides, lidocaine cross-reactivity
• Theoretical interactions with neuroleptics, antiepileptics, antidepressants not characterized
• Combinations with other Russian neuropharmacology (Cerebrolysin, Semax, Selank, Khavinson peptides) are common in Russian practice but not systematically studied

Pregnancy: contraindicated.

Breastfeeding: avoid.

Pediatric: extensively used in Russian pediatric neurology, weight-based dosing.

Athletes: not currently on WADA prohibited list.

Cortexin sits within the Russian neurological pharmacology tradition, with several related preparations:

• Cerebrolysin: the closest comparator. Porcine whole-brain peptide preparation from Ever Pharma (Austria). Similar mechanism, similar indications, slightly broader Western evidence base. Often used in similar clinical contexts
• Semax: synthetic short peptide (ACTH 4-10 analog) used in Russian neurology for stroke, TBI, cognitive enhancement. Different mechanism (melanocortin/ACTH-related), different administration (intranasal), defined single peptide rather than complex extract
• Selank: synthetic peptide for anxiety and cognitive enhancement. Different mechanism, related Russian pharmacology tradition
• Pinealon: Khavinson brain bioregulator. Different framework (synthetic single tripeptide vs complex extract) but overlapping clinical positioning for cognitive support
• Epitalon: Khavinson pineal tetrapeptide. Often combined with cerebral preparations in Russian practice

Common combinations in Russian clinical practice:

• Cortexin + Cerebrolysin: sequential courses (not concurrent) for combined cortex-specific and whole-brain effects in stroke recovery
• Cortexin + Semax: combined intramuscular polypeptide preparation plus intranasal short peptide. Used in some pediatric and stroke protocols
• Cortexin + Selank: combined neuroprotection plus anxiolytic/cognitive effects. Pediatric and adult cognitive contexts
• Cortexin + Khavinson peptides (Pinealon, Epitalon, Vesugen): system-wide Russian peptide approach. Some practitioners use sequential or combined regimens
• Cortexin + standard antiepileptics: adjunct in pediatric epilepsy (not replacement)
• Cortexin + standard stroke care: adjunct to anticoagulants/antiplatelets, thrombolysis, blood pressure management

Combinations to approach with caution:

• Pork allergy or porcine protein sensitivity: contraindicated
• Pregnancy and breastfeeding: contraindicated
• Severe allergic reaction history: cautious approach with first dose under medical observation
• Concurrent immunotherapy: theoretical caution given protein-derived nature
• Anticoagulants and antiplatelets: continue evidence-based therapy as primary intervention. Cortexin as adjunct only within Russian clinical practice context

The most actionable framing of Cortexin in 2026: this is a Russian-developed pharmaceutical drug with substantial Russian and CIS clinical use across multiple neurological indications. Unlike single-peptide compounds, Cortexin is a complex porcine cerebral cortex peptide and amino acid mixture, more comparable to Cerebrolysin than to defined synthetic peptides. The Skoromets 2017 ischemic stroke trial provides one example of methodologically rigorous evidence for the acute stroke indication. The broader Russian indication range (pediatric encephalopathy, TBI, ADHD, vascular dementia, etc.) reflects Russian clinical practice patterns and is not supported by Western-standard evidence. The compound is not FDA-approved and is not legally available as a prescription pharmaceutical in Western jurisdictions. For patients with neurological conditions in Western contexts, evidence-based standard-of-care therapies (specific to each condition) are the appropriate primary approach. Cortexin's role, where considered, is as an adjunct within Russian clinical practice frameworks or in cross-border medical contexts where Russian/CIS clinical practice patterns apply. The principal practical concerns include sourcing, quality verification, porcine protein allergy risk, the absence of Western regulatory approval, and the limited Western evidence base compared to standard neurological pharmacology. For Western patients pursuing the underlying goals (stroke recovery, cognitive enhancement, pediatric developmental support), evidence-based interventions specific to each condition have substantially stronger evidence bases.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.